Eli Lilly withdrew the application for approval of his medicine on covid – SME.sk due to the lack of interest of the EU

AMSTERDAM. The European Medicines Agency (EMA) has completed the process of ongoing evaluation of Eli Lilly against covid 9. The American pharmaceutical company withdrew the requirement to approve its anti-covid drug at its own request. Referring to Wednesday’s EMA opinion, the DPA was informed.

Low demand

In a letter to Brussels, the company stated that, given the low demand from EU Member States, it would not pay to provide it with the additional data requested by the regulator. “Given the current demand from EU member states, Eli Lilly predicts that no additional / new medicines will need to be produced in the foreseeable future,” the company said.

Eli Lilly is a combination of the monoclonal antibodies bamlanivimab and etesevimab for the treatment of patients with coronaviruswho do not need oxygen but are at high risk of severe covid.

EMA experts have been reviewing data from studies of the US covid drug manufacturer in an accelerated process since March. Despite the withdrawal of Eli Lilly from the mentioned process, the EMA stated that patients can still request this treatment on the basis of bilateral agreements between the company and individual EU member states, writes DPA.

Related article

Related article Merck will license the COVID-19 drug free of charge Read

They are considering three drugs

In September, the European Commission announced that it had signed a framework contract with the American pharmaceutical company Eli Lilly for the supply of monoclonal antibodies for the treatment of patients infected with coronavirus. The EC stated at the time that 18 Member States had already signed a joint procurement agreement for 220,000 doses of the medicine from Eli Lilly.

According to the DPA, the EMA is currently reviewing data on three covid drugs. The manufacturers of the other five have already applied for approval of their medicine for the Union market. To date, only one product, remdezivir, has been approved for the treatment of COVID-19 in the European Union.